KRas G12C inhibitors for cancer treatment

ChangeBridge: Patent Grants - Organic Chemistry (C07D)

Published March 31st, 2026

Detected March 31st, 2026

Summary

The USPTO granted patent US12590105B2 to Eli Lilly and Company on March 31, 2026, covering 24 claims for KRas G12C inhibitors and their use in treating cancer. The patent, with application number 18255713 filed on November 24, 2021, protects specific compound formulations and methods of treatment. This grant provides Eli Lilly with enforceable intellectual property rights in the United States.

View original document View source feed page

What changed

The USPTO issued patent grant US12590105B2 to Eli Lilly and Company for KRas G12C inhibitor compounds and methods of using these compounds for cancer treatment. The patent contains 24 claims covering specific molecular structures (formula R1-R5, A, B) and therapeutic applications. Inventors include David Michael Hyman, Gregory Lawrence Lackner, Sheng-Bin Peng, Bree Leigh Richey, and Chong Si.

Pharmaceutical companies and researchers developing KRas G12C targeted therapies should design around these patent claims or seek licensing arrangements with Eli Lilly. The patent provides 20-year exclusivity from the 2021 filing date, expiring in 2041. Freedom-to-operate analyses for cancer drug development programs should incorporate this granted patent.

Source document (simplified)

← USPTO Patent Grants

KRas G12C inhibitors

Grant US12590105B2 Kind: B2 Mar 31, 2026

Assignee

ELI LILLY AND COMPANY

Inventors

David Michael Hyman, Gregory Lawrence Lackner, Sheng-Bin Peng, Bree Leigh Richey, Chong Si

Abstract

The present disclosure provides compounds of the formula:
where R1, R2, R3, R4, R5, A, and B are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and salts for treating patients for cancer.